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INTRODUCTION  
 Bone tissue is capable of spontaneous self-repair, with no scarring, generating new 
tissue that is (all but) indistinguishable from surrounding bone. However, in certain 
circumstances the defect is too large (due to tumour resection, osteomyelitis, atrophic non-
unions, peri-prosthetic bone loss), or the underlying physiological state of the patient impairs 
natural healing (osteoporosis, infection, diabetes, smoking) necessitating intervention. 
Autologous bone grafting is today the gold standard for bone repair, although the costs of this 
approach are considerable due to the additional surgical procedures required to harvest the 
bone material, the consequent donor site morbidity (Silber 2003), and the risk of infection 
and complications. Additionally, this approach is hampered by the limited amount of donor 
material available for transplantation which can be prohibitive when dealing with large 
defects. To resolve these issues, both allograft- and xenograft-based strategies have been 
proposed, however the risk of rejection in the former and of zoonoses in the latter has 
reduced their clinical impact. Bone tissue engineering (BTE) is an alternative strategy that 
has been explored to fill the clinical need for autologous bone transplantation.  
 
Background 
 Almost half a century has passed since the demonstration that ectopic transplantation 
of bone marrow and bone fragments leads to the formation of de novo bone tissue which, 
when transplanted subcutaneously, is later filled with bone marrow (Friedenstein 1966, 
Tavassoli 1968). Nowadays, the notion that a set of cells present in the bone marrow stroma 
can be cultured in vitro and can regenerate fully functional bone organs in vivo is well 
accepted, although the identity and precise molecular characterisation of the cell population 
responsible is still a matter of study and debate (reviewed in (Bianco 2013, Keating 2012)) 
and the ex vivo expansion and manipulation of stromal cells derived from various sources 
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forms the foundation of the majority of current bone tissue engineering attempts to meet the 
clinical demands for bone regeneration and repair.   
Over the last 50 years, the BTE field has made significant advances towards overcoming 
the limitations of conventional methods which is particularly relevant when an underlying 
pathology calls for alternatives to the status quo. Clinically, several examples of successful 
application of tissue engineering techniques to bone reconstruction exist within the literature 
(Quarto 2001, Sandor 2014), however, on the whole, advances in basic science have not 
translated well into significantly increased clinical application. The reasons are, in part, 
financial, but additional problems such as low efficiency of differentiation, intra-patient 
variability in the differentiation potential of ex-vivo cultured cells (Schwartz 1998), as well as 
the risk of ectopic bone growth (Deutsch 2010), possible transformation (Vilalta 2008) or an 
incomplete understanding of the underlying pathways which are being manipulated with 
factors, such as transforming growth factor β (TGF-β) and bone morphogenic proteins 
(BMPs) (Chapellier 2015, Smith 2008, Siegel 2003), certainly play a role. 
 Minimal clinical adoption has prompted the exploration and adaptation of alternative 
methods including the use of stromal cells from non-bone sources (Kern 2006, Evans 2015), 
most commonly, adipose tissue (Zuk 2002, Murata 2015), but also muscle (Evans 2015); the 
development of new tissue engineering paradigms in which the focus is shifted from 
“cells+cytokines” to the engineering and in vitro optimisation of treatments as a means to 
support in vivo developmental processes by harnessing innate developmental pathways 
(Lenas 2009A, Lenas 2009B, Scotti 2010, Tonnarelli 2014); and finally, attempts to create 
“off-the-shelf” products to stimulate the regeneration of bone through adoption of 
developmental engineering principles (Bourgine 2014, Cunniffe 2015, Gawlitta 2015). 
 
Embryological Development  
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Bone forming tissues are derived from the mesoderm or a specialized part of the 
ectoderm named the neuroectoderm(Reichert 2013). Two distinct processes, called 
intramembranous and endochondral ossification, are executed by the progenitor cells in 
order to generate bone(Long 2012). During intramembranous ossification, progenitor cells 
in the connective tissue directly differentiate into osteoblasts and begin secreting osteoid 
matrix, which calcifies and later becomes lamellar bone. During endochondral ossification 
(Figure 1), progenitor cells first condensate and, through N-cadherin, upregulate Sox-9 and 
differentiate into chondrogenic cells, thus forming cartilaginous templates, for the 
subsequent bone formation(Macjke 2011). The chondrogenic cells further differentiate, 
becoming the so-called hypertrophic chondrocytes that express characteristic markers such 
as collagen type X, metalloproteniases (MMPs) and pro-angiogenic factors such as 
VEGF(Mackie 2011). Mesenchymal stem cells directly adjacent to the hypertrophic matrix 
(“perichondral cells”) form the perichondral bone collar through intramembranous 
ossification (Riminucci 1998). At the same time, vasculature is attracted towards the central 
portion and begins to invade the hypertrophic cartilage providing osteoclasts and 
mesenchymal cells. During this invasion, hypertrophic matrix calcifies and is replaced by 
woven bone (Mackie 2011, Mackie 2008). From the center, this process continues towards 
both proximal and distal ends of the bone rudiment. Near both ends, secondary ossification 
centers appear and undergo the same process. At the aricular surfaces, a thin layer of hyaline 
cartilage persists and allow for the smooth function of joints. This hyaline cartilage appears 
similar to the rudimentary cartilage template, but evidence suggests that the mesenchymal 
progenitors and the process of formation are different (Hyde 2007, Fosang 2011). At the 
border between diaphysis and epiphysis, a cartilaginous area (“growth plate”) persists until 
adulthood and is responsible for bone lengthening during growth. In fact, endochondral 
ossification takes place also in adult life in both skeletal growth and repair. 
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Figure 1: Principle of endochondral ossification. Adapted from Mackie EJ, Tatarczuch L, & Mirams M (2011) The skeleton: 
a multi-functional complex organ: the growth plate chondrocyte and endochondral ossification. The Journal of endocrinology 
211(2):109-121.  
 
Skeletal growth 
The growth plate has a well-defined hierarchical structure that reflects the various stages 
of progenitor cells differentiation (Abad 2002) (Figure 2). Close to the secondary ossification 
center of the epiphysis there is a zone of resting cartilage, which resembles the hyaline 
cartilage found in adult joints and contains few chondrocytes. The next zone contains a higher 
number of cells and is called the proliferative zone. Next to it is the pre-hypertrophic zone, in 
which the cells begin to oragnize in distinct columns. In the subsequent hypertrophic zone, 
cells increase in volume and modify their phenotype and the content of the extracellular 
matrix. In the final zone of remodeling, cells undergo apoptosis and the matrix calcifies, while 
osteoclasts and vessels invade the zone actively remodeling the matrix, followed by 
osteoblasts which deposit osteoid matrix.  
 11 
 
 
Figure 2: Organization of the growth plate cartilage. Safranin-O staining with fast green counterstaining. Adapted from 
Kim HK, Stephenson N, Garces A, Aya-ay J, & Bian H (2009) Effects of disruption of epiphyseal vasculature on the proximal 
femoral growth plate. J Bone Joint Surg Am 91(5):1149-1158. 
It is assumed that the proliferating chondrocytes have stem cells features(Abad 2002) as 
one daughter cell continues proliferating while the other differentiates progressively along 
the endochondral route. Proliferation is highly regulated by multiple pathways and feedback 
loops and can be guided by both endocrine and paracrine signals. For example growth 
hormone (GH) is secreted by the hypophysis and stimulates secretion of insulin-like growth 
factor 1(IGF-1) by liver cells and pre-hypertrophic chondrocytes, which in turn stimulates 
proliferating chondrocytes(Abad 2002). Indian hedgehog (IHH) is produced by 
prehypertrophic chondrocytes and increases proliferation and hypertrophy. On the other 
hand, parathyroid hormone related peptide (PTHrP) is mainly produced by proliferating 
chondrocytes and inhibits hypertrophy.  IHH can induce expression of PTHrP, whereas PTHrP 
suppresses IHH expression(Studer 2012). In this way a negative feedback loop is formed 
(Figure 2), which finely controls the maturation of the growth plate(van Donkelaar 2007). 
Other signals such as Wingless/Int (Wnt) or bone morphogenic proteins (BMP) can promote 
chondrocyte proliferation, whereas fibroblast growth factor (FGF) can repress it(Abad 2002). 
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Any alteration to this fine equilibrium may lead to developmental anomalies. For example, 
the most frequent disease leading to dwarfism, results from an overactivation of the FGF 
pathway(Shiang 1994).  
The main activity of chondrocytes is secreting extracellular matrix components such as 
proteoglycans and collagen type II. Other proteins are found in lower concentrations and 
mainly aid the assembly of the matrix and its interconnections(Abad 2002). Expression of 
these cartilage-specific matrix components is absolutely dependent on Sox9(Long 2012) and 
can be stimulated by tumor growth factor beta (TGFb) superfamily members (TGFb-1, BMP-
2) and FGF.  
Once the chondrocytes become hypertrophic through expression of Runt-related 
transcription factor 2 (Runx2)(Mackie 2008), they increase production of collagen type X, 
matrix metalloproteinase 13 (MMP-13), alkaline phosphatase (ALP) and IHH(Studer 2012). 
Their volume increases up to 10 fold(Bush 2008), though they do not necessarily degrade the 
ECM to make space(Abad 2002).  Thyroxin is the most important systemic regulator of 
hypertrophy(Shao 2006) and its local effect is most likely transmitted by Wnt signaling(Wang 
2007).  
The hypertrophic chondrocytes induce matrix mineralization through secretion of matrix 
vesicles, which contain akaline phosphatase and are able to nucleate hydroxyapatite crystals 
(Yadav 2011). They are also the master regulator of the endochondral ossification route as 
they actively communicate with the subsequently invading cells, for example by expressing 
vascular endothelial growth factor (VEGF) to attract endothelial cells(Ortega 2010), receptor 
aktivator of NF-kB ligand (RANKL) to attract and differentiate osteoclasts(Boyce 2008), and 
IHH / Wnt to induce osteoblast differentiation of attracted mesenchymal stem cells(Abad 
2002). At the end of hypertrophy, most hypertrophic chondrocytes undergo apoptosis(Long 
2012), however, in literature there is a growing body of evidence that few of them 
transdifferentiate towards osteoblasts and osteocytes(Yang 2014). 
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 The hypertrophic matrix is degraded by apoptotic hypertrophic chondrocytes and 
osteoclasts (Knowles 2012) through secretion of MMP-13 and MMP-9 respectively (Ortega 
2003). Endothelial cells(Abad 2002) or macrophages(Blumer 2008) can aid matrix 
degradation and may increase MMP-9 expression if MMP-13 is absent(Inada 2004). The 
degradation of the matrix releases factors which attract additional osteoclasts, endothelial 
cells and mesenchymal progenitors(Gerber 1999).  
When the bone growth finishes during young adulthood, the growth plate closes due to 
the influence of oestrogens, which deplete the pool of proliferating chondrocytes (Weise 
2001). 
 
Skeletal repair 
Bone development and repair are tightly linked and are characterized by very similar 
processes. In addition, the bone is one of the few human tissues that regenerate and not just 
repair itself with a scar. Being a mechanical-sensitive organ, according to the mechanical and 
anatomical environment, two distinct processes of fracture healing can occur. If the two 
stumps are compressed (e.g., by an osteosynthesis device) and no movement occurs, new 
osteons will directly form at both ends and continue the process of homeostasis detailed 
above(Bruder 1998). The fracture will thus be bridged by many new osteoid laminae 
originating by the two bony stumps.  
If the fracture is complex, separated by a large gap or subjected to high movement (e.g., 
dynamically stabilized by an intramedullary nail or just by a cast), a process resembling the 
embryonic endochondral ossification begins (Martin 1997, Warnke 2004). In the first stage, 
the fracture gap is filled by blood from the ruptured vessels of the endostium, periosteum and 
bone itself. The blood clot is rapidly invaded by a wave of inflammatory cells (mainly 
neutrophils and macrophages)(Warnke 2004) and mesenchymal stem cells. The latter 
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differentiate to chondrocytes and form a type of disorganized fibrocartilage which represents 
the soft fracture callus (Figure 3). This tissue has better mechanical properties than the blood 
clot and is able to temporarly stabilize the fracture(Marcacci 2007). Similarly to embryonic 
bone development but in a much less organized manner, the fibrocartilage becomes 
hypertrophic and undergoes endochondral ossification as detailed above. The tissue calcifies, 
is invaded by vessels and replaced by osteoid matrix. Initially, a woven-bone like structure is 
fomed to be then replaced by lamellar bone. In particular, the outside shell is substituted by 
compact bone, whereas the interior of the callus is replaced with bone marrow and trabecular 
structures (Figure 3). After the callus has ossified, the process of bone homeostasis will 
reshape it according to the mechanical loads and stresses, until a final shape that can 
resemble almost perfectly the one before the fracture. Of course, the final shape depends on 
the previous alignment of the fracture fragments and on the age of the person and may take 
several years to be fully reached(Bruder 1998). Although usually effective, in several clinical 
scenarios bone repair is impaired and made impossible determining a high clinical need for 
bone regeneration strategies. 
 
Figure 3: Fracture healing through endochondral ossification, safranin-O and fast green staining. Modified from Ai-Aql 
ZS, Alagl AS, Graves DT, Gerstenfeld LC, & Einhorn TA (2008) Molecular mechanisms controlling bone formation during 
fracture healing and distraction osteogenesis. Journal of dental research 87(2):107-118. 
The challenge of bone regeneration 
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Bone has the intrinsic capacity to regenerate without the formation of scar tissue, but will 
only do so in practice under certain conditions, largely related to (i) the size of the defect, (ii) 
its location and vicinity to an efficient vascular bed for vascularisation, and (iii) the 
mechanical stability of this defect. Under suboptimal conditions, complete bone regeneration 
can not occur properly and a combination of bone and scar tissues will then result in a poor 
outcome for the patient. In particular, bone loss from trauma, neoplasia, reconstructive 
surgery and congenital defects remains a major health problem, making the development of 
effective bone regeneration therapies a primary priority. Existing treatments such as the use 
of autologous or allogenic bone grafts are successful in many instances. However, 
complications due to the additional autograft surgery, limited quantity of material available 
for harvesting, and limited availability of transplant tissue from bone banks remain serious 
shortcomings. Distraction osteogenesis provides a surgical alternative but requires long 
healing times. On the other hand, the efficacy of non-viable bone obtained from cadavers and 
of synthetic materials is still under debate. The combination of osteoconductive substrates 
with osteoinductive factors (e.g., bone morphogenetic proteins) capable to recruit local 
osteoprogenitor cells holds a great promise, though optimal combinations, doses and release 
kinetics for such factors are still far from being identified and implemented in safe and 
clinically effective products. Therefore, an alternative approach that can improve the 
outcome of bone defects is highly required. 
 
Bottlenecks in cell-based approaches to bone repair 
Osteogenic grafts may be engineered by the combination of suitable scaffolds with viable 
osteoprogenitor cells. Culture-expanded, bone marrow-derived MSC have been 
demonstrated to support formation of de novo bone tissue in ectopic and orthotopic animal 
models, and have been tested in pilot clinical studies for bone repair (Quarto 2001). However, 
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their use in the routine clinical practice is hampered by a series of technical, scientific and 
clinical issues, as discussed below. 
 (i) Inter-donor MSC variability. Despite the advances in identification of putative markers 
for human MSC (Sacchetti 2008), populations of expanded human MSC are still highly 
heterogenous and extremely variable in their differentiation potential, when isolated from 
different donors, even in the same age range. This represents a major bottleneck for the 
standardization of therapeutic protocols. Indeed, it is generally accepted that only MSC from 
selected donors are capable of generating bone tissue upon ectopic implantation, and culture 
conditions allowing reproducible maintenance of MSC osteogenic capacity are yet to be 
identified. 
(ii) Need of a mineralized scaffold substrate. Human MSC have been so far reported to 
generate bone tissue exclusively through direct osteogenic differentiation, in a manner akin 
to intramembranous ossification, using a mineralized surface as “priming” substrate (Martin 
1997). The need of mineralized scaffolds, as compared to polymeric materials, results in a 
limited flexibility in the tailoring of the properties required for specific compartments/defect 
types, especially with regard to mechanical features and degradation rate.  
(iii) Cell survival after grafting. Limited MSC survival and function after implantation, 
especially in the inner core of constructs upscaled in size, is often a limiting factor for the bone 
repair efficiency. The issue of engraftment can be addressed by accelerating and improving 
construct vascularization, but no reliable and safe strategy has yet been validated in a clinical 
setting .  
(iv) Complex and costly manufacturing. Ex vivo processing of autologous cells requires 
dedicated Good Manufacturing Practice (GMP) facilities, with accredited quality management 
systems. Since these infrastructures are not easily available within the confinement of 
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hospitals or medical centers, cells and engineered grafts are typically transported to 
centralized facilities, with obvious logistics-, safety- and cost-related issues. 
As a result of these bottlenecks, it is not yet convincing that currently available MSC-based 
approaches to bone repair can lead to a cost-effective, reproducible and predictable benefit 
for patients. Therefore, there is a high need of alternative paradigms to tackle this 
challenging clinical scenario. 
 
Develomental Engineering  
Initial hopes for the application of tissue engineering to the repair and regeneration of 
bone have not yet come to fruition. Unfortunately, the unmet clinical need which generated 
the enthusiasm that surrounded TE in the 1990’s (Ingber 2006) persists today (Jakob 2012).  
Developments, particularly in animal models, have advanced the field, but the resulting 
clinical impact has been limited.  
 Traditionally, BTE has focused on tissue replacement through the in vitro/ex vivo 
generation of implants which effectively mimic the mature tissue as it is found in the adult. 
This has been achieved through the use of different cells, scaffold materials, and soluble 
factors to create a mechanical /biochemical profile that is similar to the tissue it is designed 
to replace (Ingber 2006). Scaffolds give physical strength, durability, malleability and three-
dimensional structure, allowing for custom-sized implants with specific mechano-physical 
characteristics. Different scaffold materials can be combined (Sheehy 2013) or supplemented 
with growth factors such as BMPs (Deutsch 2010). Various combinations of growth factors 
are routinely used to guide cell differentiation towards the desired phenotype; however the 
use of a limited number of factors is a long way from the complexity seen in vivo (Jakob 2012, 
Sharpe 2005). Bioreactors, using controlled perfusion of media through three-dimensional 
scaffolds recapitulate, to some degree, mechanical(Haugh 2011, Hoffmann 2015) and 
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hydrostatic forces (Steward 2012), representing a step towards replicating the tempo-spatial 
complexity of the in vivo micro-environment, something which may well be impossible to re-
create in vitro.   
 Instead of aiming to phenocopy the adult tissue-state, researchers are drawing on the 
work of developmental biology, which states that “normal tissue healing in the adult involves 
progressive remodelling of pre-existing tissue structures” (Ingber 2006) to generate grafts 
that recapitulate the immature tissue-state. By implanting the precursor-state of a tissue, or 
“organ germ” (Nakao 2010, Janicki 2010), elements of the implant can interact with natural 
developmental cues to regulate differentiation and growth, and to provide cues for cell 
invasion, remodelling, and re-vascularisation in the correct spatio-temporal context. In this 
manner we might overcome one of the greatest challenges facing TE, i.e. effectively mimicking 
the complexity of natural developmental processes, thereby leading to formation of an 
authentic mature tissue.   
 Recently, Lenas et al. (Lenas 2009A, Lenas 2009B) described a fusion of engineering 
principles and concepts from developmental biology, which they termed “developmental 
engineering” (DE). The authors outlined the utility of applying concepts such as path-
dependence, robustness, and modularity, to the manufacture of tissue grafts/implants. 
Robustness, within the context of developmental processes, refers to the ability of a system 
to function consistently despite external fluctuations. A robust developmental mechanism 
would therefore be able to cope with a degree of dissimilarity between the native tissue and 
the implant. A problem encountered when trying to gauge the characteristics necessary for 
successful stimulation of native repair processes is one of sensitivity; the basic tools and the 
limited sensitivity of currently applied methods means we are not yet able to predict whether 
a certain implant will function effectively, leading to much trial and error. However, the 
modularity of many developmental processes permits ex vivo experimentation to determine 
optimal conditions and timing for implantation to achieve the best results in vivo (Scotti 2013, 
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Liebowitz 1995). Additionally, ex vivo experiments can be used to identify markers for the 
successful completion of multi-stage developmental processes (Hall 2000). In this fashion, 
the progress of the implant can be monitored, in vivo, through the stages of development, 
highlighting where problems lie and thus, where refinement is needed. The successful 
completion of each step of development sets the stage for the next step, providing optimal 
conditions. This concept, rooted in economics, law (Gerstenfeld 2002) and biology, is called 
path-dependence and describes a situation where the outcome of one process directly 
influences the effectiveness of a successive process.  Thus, one process acts a check-point for 
the correct completion of the previous step, and at the same time completion of the previous 
step sets the stage for the following stages. In the context of bone regeneration, this is 
exemplified by hypertrophic chondrocytes which act as a natural scaffold for osteogenesis as 
well as secreting factors which orchestrate the differentiation of osteoblasts from 
perichondrial cells, as well as the mineralisation and vascularisation of the neo-bone tissue, 
restoring normoxic conditions required for optimal bone growth and bringing vital materials 
(Nakao 2007). This concept has experimental support, hypertrophic chondrocytes have been 
shown to stimulate bone regeneration in vivo, while lesser developed tissues were not as 
effective in stimulating the formation of bone tissue, likely reflecting the path-dependence of 
this process (Cunniffe 2015). 
Historically, TE has directed the formation of neo-bone through the intramembraneous 
route relying on the presence of mineralised substrate scaffolds to initiate bone growth 
through intramembraneous ossification, however more recently numerous studies illustrate 
the advantages of bone formation through endochondral ossification. As described before, 
endochondral ossification is the method by which the axial and long bones of the skeleton, 
(the vast majority of bones) are formed during embryogenesis (Ogawa 2013) and has many 
features common to bone regeneration after fracture (Sheehy 2014, Jukes 2008) including 
activation of key signalling pathways such as Indian hedgehog (IHH), parathyroid-related 
hormone receptor (PTHrP), wingless (wnt), and BMPs (although notably, the post-natal 
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environment differs from that of the developing embryo (Sheehy 2014)). The process entails 
the condensation (clustering together through cell surface receptors and adhesion molecules 
(Kronenberg 2003)) of chondrocytes, which secrete a collagenous (type II) matrix rich in 
proteoglycans. Under the control of two of the master regulators of bone development, IHH, 
and PTHrP (see (Ogawa 2003)), chondrocytes at the centre of the proto-bone organ cease to 
proliferate and become enlarged (hypertrophic), producing large amounts of type X collagen, 
directing initial mineralisation (Gerstenfeld 2003) and vascularisation through VEGF 
production, before undergoing apoptosis to leave a cartilage scaffold that will eventually be 
remodelled into mature bone(Ogawa 2013). This strategy has been exploited for bone 
regeneration; implantation of hypertrophic human bone marrow derived mesenchymal 
stromal cells (huBMSCs) in nude mice has been demonstrated to lead to the growth of ectopic 
bone structures as a result of human cells playing an active role in osteogenesis (Scotti 2010). 
BMSCs embedded in β-TCP scaffolds were able to generate frank bone in vivo, but 
chondrogenic priming was necessary for the production of bone containing bone marrow 
(BM) (Liebowitz 1995), while huBMSCs seeded on collagen type I scaffolds induced towards 
endochondral ossification formed not only bone organs, but also a fully functional BM which 
was shown to sustain haematopoiesis in lethally irradiated mice (Scotti 2013). In a previous 
study cells that were not hypertrophic at the time of implantation failed to generate bone and 
were resorbed, indicating that the developmental stage is a critical factor in dictating whether 
the implant will proceed to the next stage (Vortkamp 1997). 
There are multiple advantages to implanting chondrogenically primed cells: 
chondrocytes are more likely to survive the hypoxic in vivo environment (D’Amour 2006), 
they stimulate vascularization (Gerber 1999), and have been shown to increase bone 
formation in vivo through BMP production (Jakob 2012). Additionally, by selecting a starting 
material which most closely matches the in vivo precursor to the tissue of interest, and by 
guiding those cells though developmental stages using known markers, an intermediate form 
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of the tissue is generated which “contains all the necessary and sufficient instructive elements 
for its regeneration” (Martin 2014).  
 While the adoption of processes which mimic embryogenesis have demonstrated 
merit (Liebowitz 2015), there are salient physical, biochemical, mechanical, and 
immunological differences between the developing embryo and a mature tissue 
microenvironment (Jakob 2012, Sharpe 2005). Accordingly, we must adjust the design of 
prospective implants to reflect these differences (Tonnarelli 2014). Embryonic development 
occurs under different immunological and inflammatory settings as well as at a much smaller 
scale than in the adult, both of these factors must be addressed if embryonic processes are to 
be harnessed for the successful engineering of bone grafts.  
 Paracrine signalling gradients which function at the embryonic scale are likely to be 
inefficient in a much larger graft. Modular implants, comprising many smaller units may be 
utilised to overcome this hurdle (modular implants – cellular sheets (Yang 2007)) in addition 
to addressing some of the limitations of mass transfer such as necrosis at the core of the 
engineered tissue. 
 The immunological milieu controlling developmental processes and the influx of cells 
at the embryonic stage of bone growth remains to be fully elucidated. This is likely to be a 
crucial step if we are to fully harness the potential of developmental engineering, as immune 
factors are significant mediators of bone healing and re-growth (Sheehy 2014), which can 
result in retardation of healing, if suppressed (Burd 2003). Interestingly, this last point serves 
to highlight the differences between developmental processes underway during 
embryogenesis and those involved in the adult: while inflammation represents one of the 
main drivers of bone repair, it is absent during normal bone development. In fact, the 
significance of interleukin 1-β (IL-1β) in the re-vascularisation, mineralisation, and cartilage 
remodelling activity of huBMSCs has been illustrated and will be described in Chapter 3.  
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In conclusion, the adoption of a developmental engineering paradigm for the 
regeneration of bone represents a potential method to mitigate the enormous hurdle 
presented by largely unknown in vivo complexity. By generating pre-cursor organ germs 
based on observable in vitro-elucidated markers, and allowing natural cues to orchestrate the 
development of hypertrophic chondrocyte templates, it is foreseeable that future bone repair 
strategies will achieve clinical use. However, if we are to effectively utilise this technique, a 
clearer more complete understanding of the biochemical and mechanical forces at work in 
both the developing embryo and the adult are required. 
 
Proof-of-principle for the developmental engineering of bone 
We previously reported for the first time the capacity of expanded human MSC to 
generate frank bone tissue through an endochondral route if primed in vitro by appropriate 
stimuli and ectopically implanted in nude mice (Scotti 2010). This milestone work represents 
a proof of principle for the “Developmental Engineering” paradigm. As a matter of fact, the 
process closely recapitulated the temporal and spatial sequence of events typical of limb 
development, namely (i) cellular condensation and hypertrophic chondrogenesis, (ii) 
dependency from the activation of Indian Hedgehog (IHH) signalling, (iii) formation of a bony 
collar through perichondral ossification, (iv) MMP-mediated matrix remodelling, 
vascularization, and osteoclastic resorption, (v) bone matrix deposition over the resorbed 
cartilaginous template, and (vi) formation of a complete bone organ, including hematopoietic 
elements. Importantly, we clarified that successful implementation of the endochondral 
ossification paradigm critically required a cartilaginous template in a mature stage of 
hypertrophy, either obtained in vitro or in vivo, whereby cells strongly positive for type X 
collagen were surrounded by osteoblastic cells expressing abundant bone sialoprotein. 
However, due to the limited reproducibility of human MSC from different donors, the 
approach was validated using cells from selected primary cells with kown chondrogenic 
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potential. Moreover, the paradigm was developed with a small scale, scaffold-free transwell 
model and required to be scaled-up in size in order to be proposed for a clinically relevant 
scenario.  
 
 
Figure 4. Remodelling of the cartilaginous template after 4 and 8 weeks in vivo. (a, e, i) Four weeks after implantation, 
early hypertrophic samples had differentiated further towards hypertrophy, displaying larger lacunae, Col X accumulation and 
initiated BSP deposition in the outer rim. (b, f, j) Eight weeks after implantation, early hypertrophic samples had differentiated 
even further. This was evidenced by a decrease in GAG accumulation, while Col X was maintained and BSP had also been 
deposited within the cartilaginous core. (c, g, k) After 4 weeks, late hypertrophic specimens had undergone more intense 
remodeling, such that GAG and Col X levels were reduced, while BSP had already been deposited within the cartilaginous core. 
(d, h, l) After 8 weeks, the cartilaginous template was almost completely resorbed: bone structures substituted the GAG positive 
areas in the central region, while Col X and BSP positive areas were restricted to scattered islands. All the pictures were taken at 
the same magnification, scale bar = 200μm. Taken from Scotti C, et al. (2010) Recapitulation of endochondral bone formation 
using human adult mesenchymal stem cells as a paradigm for developmental engineering. Proceedings of the National Academy 
of Sciences of the United States of America 107(16):7251-7256. 
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Figure 5. Bone tissue is generated over the cartilaginous template after 8 weeks in vivo. a) Microtomography 
showing bone trabeculae after 5 weeks of in vitro culture and 8 weeks in subcutaneous pouches of nude mice. b) Histology 
confirming the bony nature of the stractures highlighted by the microtomography. c) Histology showing hematopoietic elements 
and adipose tissue within the mature bone, confirming the generation of a complete bone organ. Taken from Scotti C, et al. (2010) 
Recapitulation of endochondral bone formation using human adult mesenchymal stem cells as a paradigm for developmental 
engineering. Proceedings of the National Academy of Sciences of the United States of America 107(16):7251-7256. 
 
A crucial achievement of our previous studies was that during in vitro culture and in vivo 
implantation, expanded human MSC recapitulated the finely orchestrated events occurring 
during limb development. (Figures 5 and 6). These data demonstrate that human MSC from 
adult individuals – if appropriately manipulated – maintain the capacity to undergo an 
endochondral ossification process by closely recapitulating embryonic pathways involved in 
limb development: this represents an attractive validation of the “Developmental 
Engineering” paradigm. In principle, according to this feature, the potential of hMSC to 
achieve hypertrophic differentiation, enter the endochondral route and subsequently 
determine bone formation could be even further enhanced with the use of agonists of IHH 
pathway. 
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Figure 6. Activation of pathways involved in endochondral ossification (Scotti et al., 2010). a), b) After implantation 
for 4 weeks, representative genes, assessed by in situ hybridization (IHH, and GLI1 as IHH effect mediator) were expressed. c), 
d) Functional inhibition of the IHH pathway through administration of cyclopamine blocked the differentiation and maturation 
of the cartilaginous templates, as assessed by Safranin-O stain. e) mRNA expression of genes involved in IHH signalling (IHH, 
GLI1, PTCH1), PTH signalling (PTHLH, PTHR1), as well as chondrogenic/hypertrophic genes (Col II, VEGF), and osteogenic genes 
(Cbfa-1, Col I, BSP) confirmed suppression of the endochondral route by cyclopamine. Taken from Scotti C, et al. (2010) 
Recapitulation of endochondral bone formation using human adult mesenchymal stem cells as a paradigm for developmental 
engineering. Proceedings of the National Academy of Sciences of the United States of America 107(16):7251-7256. 
 
The described principles have lead to the development of engineered hypertrophic 
cartilage as a bone substitute (Scotti 2010), which displays advantageous properties such as 
resistance to hypoxia (Sheehy 2012, Grimshaw 2000) and gradual vascular invasion(Sheehy 
2015). This type of graft has been used in orthotopic models such as calvarial(Kuhn 2014) or 
femoral segmental defects (van der Stok 2014, Harada 2014) and with strategies as diverse 
as monolithic constructs (Harada 2014), pellets between 1-3mm  in diameter (Bahney 2014) 
or complex modified structures (Cunniffe 2015). Generation of greater tissue volumes has 
been proposed using bioreactor systems(Kock 2014, Hoffmann 2015). As a next biomimetic 
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step, co-cultures of hypertrophic cartilage with endothelial cells have been performed to 
improve mineralization(Freeman 2015). For clinical applications of engineered hypertrophic 
cartilage, a remaining drawback is the use of autologous MSC to form the graft. Although 
necessary to prevent immunologic rejection, autologous MSC use means additional extraction 
and a significant time-delay. The interdonor variability encountered with MSC (Solchaga 
2011) may also lead to unpredictable outcomes. For this reason, there is a high need of bone 
regeneration strategies characterized by a standardized bone-forming potential and a 
sustainable cost for the payers. 
Devitalized Extracellular Matrices 
The use of allogeneic hypertrophic cartilage of high quality would be possible if 
immunologic rejection could be prevented. This could be achieved through removal of cells, 
since matrix constituents are hihgly conserved and may even prevent an adaptive immune 
response(Bollyky 2009). Indeed, the extracellular matrix itself may hold sufficient cues to 
instruct cell function and identity(136). Moreover, in the case of hypertrophic cartilage, 
apoptosis of hypertrophic chondrocytes(Crapo 2011) and the release of matrix bound signals 
such as VEGF through MMP-mediated matrix degradation are part of the natural 
developmental and growth processes. Thus devitalization of allogeneic hypertrophic 
cartilage by chemical or physical means or induction of apoptosis(Bourgine 2013) can be an 
alternative to the use of patient derived grafts. For these reasons, a devitalized endochondral 
“engineered extracellular matrix” (eECM) would be an attractive and clinical-compliant 
strategy to achieve bone regeneration at the most challenging sites.  
In fact, from a clinical and commercial standpoint, an eECM with the capacity to induce 
bone formation would be highly attractive. In particular, it would: (i) avoid autologous cells 
processing, which is time consuming and costly; (ii) lead to standardized “off the shelf” 
products; and (iii) by-pass inter-individual variability in the cell differentiation capacity, 
which severely limits clinical applications of MSC-based approaches, thus making the clinical 
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translation of this approach more cost-effective, feasible and effective than typical tissue 
engineering strategies.  
General Aim of the Thesis 
Briefly, this thesis includes the translational effort towords the development of a clinical 
“product” from an innovative scientific concept. In other words, upon demonstration of the 
potential of the developmental engineering paradigm (scotti 2010) for the regeneration of 
the bone tissue, I aimed at developing a clinically-relevant application of this concept.  This 
strategic goal lead me to (i) the extension of this concept to an upscaled model that allowed 
showing unprecedented features of engineered “bone organ”; (ii) the application of the 
paradigm to the process of bone repair, that is tightly linked to bone development; and (iii) 
the development of an innovative method of devitalization that allows to preserve key factors 
harbored within the ECM in order to show the potential for an “off-the-shelf” product for bone 
regeneration.  
 
Specific Aims of the Chapters 
The scientific work is presented in the form of three scientific publications. 
Chapter 2 Engineering Of A Functional Bone Organ Through Endochondral 
Ossification 
In this chapter, it was hypothesized that human MSC primed through endochondral 
ossification can engineer a scaled-up ossicle with features of a “bone organ”, including 
physiologically remodeled bone, mature vasculature and a fully functional haematopoietic 
compartment.  This represents the essential backbone on which the subsequent translational 
works have been based, as well as the prerequisite for the controlled manipulation of HSC 
niches in physiology and pathology.    
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Chapter 3 Interleukin-1beta Modulates Endochondral Ossification By 
Human Adult Bone Marrow Stromal Cells 
Inflammatory cytokines present in the milieu of the fracture site are important 
modulators of bone healing and they are not present during embryonic development. This 
represents a crucial factor for a successful translation of the developmental engineering 
paradigm. In this chapter, in order to duplicate some features of the fracture callus, we 
investigated the effects of interleukin-1β (IL-1β) on the main events of endochondral bone 
formation by human MSC, namely cell proliferation, differentiation and 
maturation/remodeling of the resulting hypertrophic cartilage.  
Chapter 4 Osteoinductivity Of Engineered Cartilaginous Templates 
Devitalized By Inducible Apoptosis 
A key hurdle that limits translation to the clinic of regenerative therapies is the use of 
autologous cells. In this chapter, we hypothesized that the preservation of the ECM integrity, 
serving as a reservoir of multiple growth factors at physiological levels, is a key pre-requisite 
to recruit and instruct endogenous progenitors to initiate bone regeneration and that this 
capability can be used to engineer cell-free, off-the-shelf biomaterials to be used for the 
regeneration of the bone tissue. In particular, we aimed at inducing de novo bone organ 
formation using cell-free hypertrophic cartilage templates, devitalized by apoptotic induction 
through retroviral transduction of an inducible Caspase-9 (inducible Death System – iDS). The 
results reported in this chapter outline a broader paradigm in regenerative medicine, based 
on the engineering of cell-based but cell-free niches capable to recruit and instruct 
endogenous cells to the formation of predetermined tissues. 
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DISCUSSION  
 In this thesis, three papers are discussed. In the first, we upscaled the previously 
developed model in order to generate a bone organ that allowed us to better describe the 
tissue remodeling and the interplay between bone and haematopoietic cells. In the second, 
we further improved the model by making it more similar to bone repair, by adding a pro-
inflammatory cytokine (IL-1β) to the system and evaluating its effect of the bone remodeling 
and haematopoietic cells processes. In the third, we worked towards developing an eECM by 
retroviral transduction of an inducible Capsase-9 of human BMSCs. In these three consecutive 
works, we highlighted the potential for the endochondral route to be translated into clinical 
practice and progressively streamlined our model by making it more similar to bone repair 
and more clinically compliant. Further in vitro and in vivo studies are currently ongoing in 
order to fully elucidate the potential of this strategy. 
 With the objective of bone repair in a manner which recalls natural healing processes, 
both cell-based and cell-free methods have been utilised, both have advantages, but currently 
cell-based therapeutic strategies are the status quo in pre-clinical science. This usually 
comprises BMSCs which have been extracted and either re-injected intra-operatively or 
cultured ex vivo for several passages to generate many more cells which are then re-injected 
in their current state, or, more commonly, seeded on a three-dimensional scaffold material. 
Cell-based strategies, most often utilising BMSCs, have been shown to be more successful at 
stimulating bone healing than cell-free approaches, resulting in greater mineralisation, 
ossification, and increased angiogenic potential (Cunniffe 2015, Gawlitta 2015, Kon 2000). 
These results are supported by data showing cell-based techniques to be clinically 
advantageous (Liebergall 2013, Dallari 2007). This has obvious implications for the choice of 
cell source, since a cell containing detectable genetic, epigenetic, proteomic modifications 
which are optimal for a particular developmental path is not only more likely to produce a 
higher quality final product, but is also likely to contain additional characteristics which the 
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limited and basic range of tests at our disposal cannot gauge. That said, ADSCs, which had low 
intrinsic bone-forming potential and produced no neo-bone in their un-induced state, when 
chondrogenically primed deposited a proteoglycan-rich cartilaginous matrix and were able 
to generate a similar amount of bone as non-induced BMSCs (Brocher 2013). This suggests 
that by re-routing ADSCs through endochondral ossification, a precursor state is created that 
favours bone formation. It is noteworthy that despite the successful re-routing of ADSCs, 
uninduced BMSCs achieved better final results, perhaps reflecting intrinsic factors that 
predispose them to bone formation (Shao 2013). 
However, the downsides to autologous cell-based therapy are significant, and can be 
prohibitive in some cases. The rarity of BMSCs can be limiting to the point of rendering cell 
extraction unfeasible (especially in the elderly and the ill) and too few Colony Forming Unit -
fibroblast (CFU-f) within a BM extract will fail to generate neo-bone tissue (Braccini 2005). 
Even in healthy individuals, cell extraction requires an additional procedure which carries 
added morbidity. Eliminating the need for extra surgery is a strong motivation behind intra-
operative techniques which, while avoiding the time-expensive and laborious GMP handling 
of cells in the laboratory, are also limited by the number of BMSCs available for re-injection.  
 Cell-free technologies have been proposed as an alternative to sidestep many of the 
barriers associated with cell-based techniques for bone-specific and other areas of tissue 
engineering. A product which is available “off-the-shelf” following decellularisation and 
sterilisation, has obvious practical advantages from a surgical perspective, such as the 
reduction of intra-patient variability, and would allow the selection and preparation of the 
implant prior to surgery. Additionally, the implant can be re/cellularised with autologous 
BMSCs prior to use if sufficient BMSCs are available (Gawlitta 2015). Also, a sterile acellular 
product would be amenable to storage and thus easily transported to areas of need, such as 
impoverished nations where the resources for preserving cell-based products might be 
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lacking. All of these reasons would act to increase the clinical up-take and motivated our 
research in this direction. 
 Many recent studies have attempted to mimic the inherent complexity of the 
biological microenvironment, in terms of architecture and biochemical constituents, through 
the use of decellularised extracellular matrix (ECM) from a variety of animal sources, both 
human (Badylak 2012) and non-human (Irvine 2011). The latter option presents the 
possibility of benefiting from existing slaughter processes to access a large volume of material 
for decellularisation. The risk of zoonoses, especially prion diseses, can be reduced by 
sourcing animals from prion-free island populations (Lun 2010). The use of cell lines derived 
from either human or non-human animals to produce a functional eECM presents the 
possibility of standardisation, reducing donor-to-donor variability. 
 The concept of using eECM as bone substitutes could represent a significant 
innovation and breakthrough in the field of bone regeneration. The prospective of generating 
standardized off-the self-products with customizable properties to provide a consistently 
effective solution for several clinical scenarios render this approach highly attractive from 
both clinical and commercial standpoints. The unavoidable increased complexity of eECM as 
compared to native- or synthetic- derived ECM substitutes could be compensated by their 
superior biological performance and customization potential that allow not only to support 
but to actively drive tissue repair. However, the successful implementation of this approach 
requires deep understanding of the complex events of the bone healing process that can be 
driven and finely coordinated by the bioactivity of “smart” materials derived from eECM 
approach. In this context, multidisciplinary efforts have led to the establishment of methods 
to provide robust biomimetic protocols inspired from biological processes occurring during 
embryonic tissue development and further revised in the context of adult bone tissue repair, 
taking into consideration immune and mechanical aspects. The multitude of parameters 
involved in this approach may also require the use of miniaturized high-throughput devices 
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(e.g. microfluidic devices) followed by combinatorial analyses in order to define the minimal 
set of necessary eECM signals which are required for predictable instruction of bone 
regeneration. 
Prospectively, established conditions for the generation of customized eECM can be 
translated to suitable bioreactor devices to address the challenges of engineered graft 
production by providing both a more sustainable manufacturing process and a more 
clinically-compliant procedure. Indeed by using a bioreactor-based approach one could 
possibly streamline the processes of ECM production and its decellularization within the 
same device, reducing thus complexity and cost in the manufacturing. Moreover, the 
reproducible behavior of the cell-lines together with the monitor capabilities of bioreactor 
technologies may facilitate the establishment of the relevant cell culture parameters and 
release criteria, predicting ultimately grafts quality. Obviously, GMP-compliant concepts 
related to the manufacturing devices and processes need to be introduced to conform to 
regulatory guidelines for the production of engineered grafts for clinical use.  
With regard to bone engineering, the works presented in this thesis and others that have 
been published by other groups suggest that the endochondral route is a promising  template. 
Previously, hypertrophic chondrocytes derived from human BMSCs were shown to be 
remodelled and replaced by frank bone tissue, including a functional haematopoietic 
compartment (Scotti 2010). Accordingly, decellularised hypertrophic cartilage has been used 
as a template to stimulate the regeneration of bone material through endochondral pathways, 
promoting the invasion and proliferation of host cells  – although in the case of Cunniffe et al. 
(Cunniffe 2015) the implant was not 100% decellularised and was implanted in a nude mouse 
model. As shown in the third paper discussed in this thesis (Chapter 4), we proposed to induce 
apoptosis by retroviral transduction of an inducible Caspase-9 of hypertrophic chondrocytes, 
in order to decellularise ECM and, therefore, generate an eECM for bone regeneration. 
Importantly, this was shown to be superior to a standard freeze-thaw protocol for the 
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regeneration of bone. In our work, post-apoptotic cartilage and implants containing live 
BMSCs, but not non-hypertrophic cartilage, underwent extensive remodelling and after 12 
weeks in vivo tested positive for the presence of a BM space, although implants containing 
live cells outperformed the “apoptosed” tissue. Elsewhere, non-hypertrophic cartilage was 
shown to be inferior to hypertrophic constructs in a mouse femoral defect model, where only 
the latter were successful in bridging the defect (Cunniffe 2015).  
 To date, the use of cell-free techniques has yet to demonstrate equivalence to cell-
containing preparations. Developments in the methods used for decellularisation will 
undoubtedly result in more effective materials, due to greater retention of ECM-associated 
molecules with simultaneous removal of cellular material, as it happens with the method we 
proposed, to yield bone-engineering products with off-the-shelf convenience, as well as low-
maintenance storage, and increased customisation. 
 
 
 
 
 
 
 
 
CONCLUSIONS 
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Intrinsic bone repair mechanisms are highly effective, but in certain cases external 
intervention is required.  In some instances, BTE has been shown to provide clinical relief, but 
improvement in BTE technologies are required to allow its application to greater numbers of 
patients, particularly those to whom traditional bone grafting procedures are unfeasible.  
BMSCs form bone and BM in vivo which is essential if creation of the HME is required. 
This is a striking difference compared to typical tissue engineering methods resembling 
intramembranous ossification. However, the factors (genetic, epigenetic, proteomic, etc.) 
responsible for the pre-destination of BMSC to form functional bone and BM are unknown.  
Likely a fraction of these factors driving BMSC to form bone containing BM will also regulate 
additional steps in skeletal development and remodelling allowing cells to correctly react to 
autocrine and paracrine developmental signals.  
Regardless of cell source, currently live cell-based implants tend to be superior to cell-
free, and decellularised alternatives at regenerating bone tissue. Recent advances in 
decellularisation protocols are bringing the performance of decellulariced and devitalised 
tissues to ever greater levels, approaching that of vital implants, with the added value of 
storage, transportation and the possibility of allogenic or xenogenic-derived grafts to 
circumgate the difficulties in obtaining autologous cells for bone regeneration and repair. 
Recent strategies in bone repair and regeneration have sought to embrace a 
developmental engineering approach, following as closely as possible the natural processes 
of bone development through the remodelling of hypertrophic cartilage templates via 
endochondral ossification. Our work represents one of the first efforts aimed at translating 
the scientifically fascinating but clinically challenging paradigm of developmental 
engineering to the regeneration of the bone tissue. In particular, we provided the first proof 
that human adult MSCs can undergo the full endochondral route and generate a bone organ, 
triggering the development of a new strategy in bone regeneration. The three papers 
presented in this thesis are tightly connected in the effort of streamlining the implementation 
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of the endochondral route to the clinic. Of course, further improvements and simplifications 
are required to really make this happen.  
In the Introduction, I outlined bottlenecks that limit the translation to the clinic of 
experimental bone regeneration strategies. In the following, I discuss how the proposed 
strategy address these issues and can be used to overcome current hurdles. 
(i) Inter-donor MSC variability. This remains a relevant issue in all MSC-based 
regenerative therapies. However, this can be overcome by providing a decellularized 
hypertrophic cartilage eECM, to be then re-cellularized in situ. In fact, the manufacturing of 
such an eECM can be obtained with allogeneic MSC, previously tested as per endochondral 
potential, and subsequently decellularized (e.g., as shown in Chapter 4) to minimize eECM 
immunogenicity. 
(ii) Need of a mineralized scaffold substrate. This issue has been totally overcome by 
the endochondral approach to bone regeneration. In fact, being based on the chondrogenic 
differentiation of MSCs, a mineralized substrate is not strictly needed by this approach. Of 
course, some degree of mineralization may help in order to improve bone formation but it is 
not mandatory with this strategy, allowing for the use of more flexible ECM, hydrogel or 
polymer material. 
(iii) Cell survival after grafting. In our work we showed that bone formation can be 
achived independelty from cell survival, with a decellularized eECm approach. In addition, we 
showed the role of both cell survival and cell apoptosis following implantation. This reflects 
the dual role of hypertrophic chondrocyte that can either participate to bone formation at 
some extent or massively die through apoptosis and leave the ECM to be colonized by skeletal 
progenitor cells and hematopoietic cells. This is also confirmed by the fact that, although 
being able to generate bone tissue with hematopoietic compartments, a fully decellularized 
ECM can be remodeled into a bone organ at a lesser extent than vital tissues.  
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(iv) Complex and costly manufacturing. We are currently addressing this issue by 
developing bioreactor-based culture of hypertrophic cartilage templates. Bioreactor culture 
allows out-scaling and automating the production of tissues, making it more affordable, 
controlled and reproducible.  
In an effort to further streamline bone regeneration strategies, future research will be 
aimed at dissecting the intricate interplay between the ECM and cells, in order to identify 
potential molecular targets and allow for the development of biologics capable to trigger the 
execution of the endochondral ossification route. For example, as growth factors and 
cytokines harbored within the ECM can trigger the process, one could speculate that even 
only the secretome of hypertrophic chondrocytes may be enough to do so. And that, also, a 
combination of such a secretome with a scaffold providing structural stability can be a more 
efficient solution compared to an eECM. In addition, a biologic or a small molecule 
characterized by a high safety (e.g., compared to BMPs) and a very specific mode of action 
could be even more feasible to be manufactured and commercialized, from a pharmacologic 
standpoint. However, as mentioned above, considering the challenging mechanical demands 
to the bone tissue, a combination approach including a scaffold biomaterial (being either an 
ECM or a synthetic biomaterial) will always be required. 
By combining all the abovementioned concepts, we can envision a large scale production 
of hypertrophic cartilage tissue, in an automated, highly controlled bioreactor manufacturing 
system, using engineered human cells (e.g., MSCs or iPS) with high endochondral potential 
and capable to undergo apoptosis upon induction. This will allow the generation of a series 
of cost-effective custom eECMs to be used for tissue regeneration at the most challenging 
sites. 
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